“IL-33/IL-31 Axis” in Allergic and Immune-Mediated Diseases

Dear Colleagues,

Several allergic and immunologic diseases including asthma, food allergy (FA), chronic spontaneous urticaria (CSU), atopic dermatitis (AD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and inflammatory bowel diseases (IBDs) are characterized by the involvement of Th2 immunity.  Several mediators lead to IgEs production, thus including key cytokines like IL-4, IL-5, and IL-13. Among them, IL-31 and IL-33 have been recently studied as novel biomarkers and future therapeutic targets for allergic and immunological disorders. IL-31 is a proinflammatory cytokine, it regulates cell proliferation, and it is involved in tissue remodeling. IL-33, acting through its receptor ST2L, is an alarmin cytokine from the IL-1 family, whose expression is mediated by tissue damage. The latter has a pleiotropic effect, as it may modulate specific and innate immune cells functions.

To date, several researchers have been investigated the involvement of IL-31 and IL-33 in several allergic and immune-mediated diseases. Further studies are needed in order to understand the future applications of these molecules as novel therapeutic agents.

In this Special Issue, we will address the role of IL-31 and IL-33, other related-cytokines/receptors, or signaling molecules that play a role in the pathogenesis of allergic and immune-mediated diseases. We will consider all reports, without restrictions in the animal or cellular model used. We encourage researchers to contribute experimental papers or review articles.

Prof. Dr. Giuseppe Murdaca
Assoc. Prof. Sebastiano Gangemi
Dr. Monica Greco
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.